Titan Pharmaceuticals Files Proxy Materials

TL;DR

Titan Pharma filed proxy docs, likely for shareholder votes. Keep an eye on this.

AI Summary

Titan Pharmaceuticals, Inc. filed a Definitive Additional Materials proxy statement on August 14, 2025. The filing relates to a proxy statement pursuant to Section 14(a) of the Securities Exchange Act of 1934. The company is incorporated in Delaware and its fiscal year ends on December 31st.

Why It Matters

This filing indicates that Titan Pharmaceuticals is proceeding with corporate actions requiring shareholder approval or notification, which could impact the company's future direction and shareholder rights.

Risk Assessment

Risk Level: low — This is a routine filing of proxy materials, not indicating any immediate financial distress or significant corporate event.

Key Players & Entities

• Titan Pharmaceuticals, Inc. (company) — Registrant
• August 14, 2025 (date) — Filing Date
• Securities Exchange Act of 1934 (legal_document) — Governing Law

FAQ

Key Financial Figures

• $0.001 — ompany from 49,996,000 Ordinary Shares, $0.001 par value each and 4,000 Preferred Shar

Filing Documents

• formdefa14a.htm (DEFA14A) — 29KB
• 0001641172-25-024185.txt ( ) — 30KB

From the Filing

UNITED SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant Filed by a Party other than the Registrant Check the appropriate box: Preliminary Proxy Statement Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) Definitive Proxy Statement Definitive Additional Materials Soliciting Material under §240.14a-12 Titan Pharmaceuticals, Inc. (Name of Registrant as Specified In Its Charter) (Name of Persons(s) Filing Proxy Statement, if other than the Registrant) Payment of Filing Fee (Check all boxes that apply): No fee required Fee paid previously with preliminary materials Fee computed on table in exhibit required by Item 25(b) per Exchange Act Rules 14a-6(i)(1) and 0-11 EXPLANATORY NOTE On July 22, 2025, Titan Pharmaceuticals, Inc. (“Titan”) filed a definitive proxy statement (the “Proxy Statement”) with the Securities and Exchange Commission in connection with its Special Meeting of Stockholders to be held on August 26, 2025 (the “Special Meeting”) for purposes of approving a business combination transaction. On August 14, 2024, Black Titan Corporation (“Black Titan”) filed a supplement updating information in the proxy statement/prospectus included in the registration statement on Form F-4, Registration No. 333-287709. Titan is hereby filing this supplement (the “Supplement”) to the Proxy Statement in order to incorporate the supplement filed by Black Titan. Except as specifically supplemented by the information contained below, all information set forth in our Proxy Statement remains unchanged. You should refer to the full Proxy Statement for complete details regarding the Special Meeting and each of the proposals. SUPPLEMENT TO PROXY STOCKHOLDERS OF TITAN PHARMACEUTICALS, INC. AND PROSPECTUS FOR UP TO 7,210,800 ORDINARY SHARES OF BLACK TITAN CORPORATION This supplement updates information in the proxy statement/prospectus, dated July 22, 2025, included in the registration statement on Form F-4, Registration No. 333-287709 (the “ Registration Statement ”), filed by Black Titan Corporation, f/ka/ BSKE Ltd., a Cayman Islands exempted company limited by shares (“ PubCo ” or “ Black Titan ”). Black Titan filed the Registration Statement, and Titan Pharmaceuticals, Inc., a Delaware corporation (“ Parent ” or “ TTNP ”) filed a proxy statement, in connection with a special meeting of holders of TTNP Common Stock scheduled to be held August 26, 2025 (the “ Special Meeting ”). At the Special Meeting, holders of TTNP Common Stock are being asked to vote to approve a Merger and Contribution and Share Exchange Agreement, dated August 19, 2024, by and among Black Titan, TTNP, TTNP Merger Sub, Inc., a Delaware corporation and a direct wholly owned subsidiary of Black Titan, and TalenTec Sdn. Bhd., f/k/a KE Sdn. Bhd., a Malaysia private limited company, the Business Combination contemplated thereby, and related proposals. The proxy statement/prospectus provides detailed information about the Business Combination and other matters to be considered at the Special Meeting. You are encouraged to carefully read the entire document, including the annexes, as well as this supplement. You should, in particular, carefully consider the risk factors described in “Risk Factors” beginning on page 41 of the proxy statement/prospectus. NEITHER THE U.S. SECURITIES AND EXCHANGE COMMISSION NOR ANY STATE SECURITIES REGULATORY AGENCY HAS APPROVED OR DISAPPROVED THE TRANSACTIONS DESCRIBED IN THE PROXY STATEMENT/PROSPECTUS OR ANY OF THE SECURITIES TO BE ISSUED IN THE BUSINESS COMBINATION, PASSED UPON THE MERITS OR FAIRNESS OF THE BUSINESS COMBINATION OR RELATED TRANSACTIONS, OR PASSED UPON THE ADEQUACY OR ACCURACY OF THE DISCLOSURE IN THE PROXY STATEMENT/PROSPECTUS OR THIS SUPPLEMENT. ANY REPRESENTATION TO THE CONTRARY CONSTITUTES A CRIMINAL OFFENSE. This supplement to the proxy statement/prospectus is dated August 14, 2025. Amendments to Memorandum and Articles of Association. On August 11, 2025, Black Titan adopted its second amended and restated memorandum and articles of association (the “ Articles ”) by special resolution passed by Black Titan shareholders, to increase the share capital of the Company from 49,996,000 Ordinary Shares, $0.001 par value each and 4,000 Preferred Shares, par value $0.001 each, to 1,00,000,000 Ordinary Shares, $0.001 par value each and 50,000,000 Preferred Shares, par value $0.001 each. The Articles were filed with the Registry of Corporate Affairs in the Cayman Islands. Proposed Financing On August 8, 2025 Black Titan entered into a Placement Agency Agreement with ARC Group

View Full Filing

View this DEFA14A filing on SEC EDGAR